Funding

Dr. Springer has received funding for research in his Translational Cell Biology of Parkinson's Disease Laboratory from a variety of organizations, including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the Department of Defense (DOD), the Florida Department of Health (FDOH), the Michael J. Fox Foundation for Parkinson's Research (MJFF) and the American Parkinson Disease Association (ADPA).

Grants

Investigator & Role Grant Title Funding Source Duration
Wolfdieter Springer, Ph.D., principal investigator Molecular mechanisms of PINK1-PRKN-directed mitochondrial quality control (2R01/RF1 NS085070) National Institute of Neurological Disorders and Stroke (NINDS) 08/01/14-07/31/24
Wolfdieter Springer, Ph.D., co-principal investigator, Center Without Walls (CWOW), Project #4 Synergistic interactions of amyloid-beta and alpha-synuclein in Lewy body dementia (U54 NS110435) National Institute of Neurological Disorders and Stroke (NINDS) 10/01/19-06/30/24
Wolfdieter Springer, Ph.D., co-principal investigator Mitochondrial Sirtuin 3 in Parkinson's disease (R01 N110085) National Institute of Neurological Disorders and Stroke (NINDS) 06/01/19-05/30/24
Wolfdieter Springer, Ph.D., principal investigator Determining PINK1 and PRKN enzyme activities in vivo (ID 019046) Michael J. Fox Foundation for Parkinson's Research (MJFF) 04/15/21-10/15/22
Wolfdieter Springer, Ph.D., principal investigator Early-onset Parkinson's disease is a mitochondrial disease: A nigral mitochondrial cytopathy (W81XWH-17-1-0248) Department of Defense (DOD) 08/15/17-08/14/22
Wolfdieter Springer, Ph.D., principal investigator Biomarker for mitophagy pathway activation (ID 019258) Michael J. Fox Foundation for Parkinson's Research (MJFF) 12/01/20-05/31/22
Wolfdieter Springer, Ph.D., principal investigator Validation of novel pS65-Ub antibodies (ID 17399) Michael J. Fox Foundation for Parkinson's Research (MJFF) 10/01/19-04/02/22
Wolfdieter Springer, Ph.D., principal investigator Elucidating cell type-specific PINK1 and PRKN expression in vivo (ID 021186) Michael J. Fox Foundation for Parkinson's Research (MJFF) 01/03/22-01/02/22

Completed grants

Investigator & Role Grant Title Funding Source Duration
Wolfdieter Springer, Ph.D., principal investigator Functional assays to identify novel regulators of mitochondrial quality control (ID 15007) Michael J. Fox Foundation for Parkinson's Research (MJFF) 10/17/17-12/01/21
Wolfdieter Springer, Ph.D., principal investigator Selective autophagy in Alzheimer's disease and related dementias (R56 AG062556) National Institute on Aging (NIA) 08/01/19-07/31/20
Wolfdieter Springer, Ph.D., principal investigator Validation of novel, selective autophagy biomarkers in Alzheimer's disease (9AZ10) Florida Department of Health (FDOH), Ed & Ethel Moore Alzheimer's Disease Research Program 02/01/19-01/31/20
Wolfdieter Springer, Ph.D., principal investigator pS65-Ub as a biomarker for Parkinson's disease (ID 8948.03) Michael J. Fox Foundation for Parkinson's Research (MJFF) 08/01/18-01/31/20
Wolfdieter Springer, Ph.D., principal investigator Characterization of new Parkin activation mutants (ID 14681-01) Michael J. Fox Foundation for Parkinson's Research (MJFF) 12/01/17-11/30/19
Wolfdieter Springer, Ph.D., principal investigator p-Ub and mitophagy as biomarkers for Parkinson's disease (ID 8948.02) Michael J. Fox Foundation for Parkinson's Research (MJFF) 09/01/16-12/31/17
Wolfdieter Springer, Ph.D., principal investigator Hit-to-Lead Optimization of Parkin activators through structure-function-analyses (ID 8948.01) Michael J. Fox Foundation for Parkinson's Research (MJFF) 06/18/15-12/17/16
Wolfdieter Springer, Ph.D., principal investigator Identification of Parkin activators through structure-function Analyses (ID 8948) Michael J. Fox Foundation for Parkinson's Research (MJFF) 12/01/13-04/30/15